Amylin vs GLP-1: What’s the Difference?

GLP-1 has become one of the most recognised hormone pathways in modern metabolic research.

But another peptide hormone is attracting increasing scientific attention: amylin.

The two are sometimes discussed together because both participate in metabolic regulation, but amylin and GLP-1 are not the same hormone and don’t act through the same receptor system.

Understanding the difference also helps explain why researchers are investigating compounds such as cagrilintide, CagriSema and zenagamtide.

What Is GLP-1?

GLP-1 stands for glucagon-like peptide-1.

It is a naturally occurring peptide hormone produced primarily by specialised intestinal cells following nutrient intake.

GLP-1 interacts with the GLP-1 receptor, which is found in several tissues.

Researchers have studied GLP-1 signalling extensively because of its involvement in processes including glucose-dependent insulin secretion, glucagon regulation, gastric emptying and appetite-related signalling.

The pathway subsequently became an important target for pharmaceutical research.

What Is Amylin?

Amylin is also a naturally occurring peptide hormone, but it comes from a different biological system.

Human amylin consists of 37 amino acids and is produced primarily by pancreatic beta cells.

It is normally released alongside insulin.

Researchers have investigated its involvement in several physiological processes, including satiety signalling, gastric emptying and post-meal glucagon regulation.

So while GLP-1 and amylin can influence some overlapping physiological processes, they do so through different signalling systems.

Amylin vs GLP-1: The Fundamental Difference

The simplest distinction is their biological origin and receptor activity.

GLP-1 is primarily an intestinal incretin hormone and signals through the GLP-1 receptor.

Amylin is primarily co-secreted with insulin by pancreatic beta cells and acts through amylin receptor complexes.

They are therefore separate hormones rather than different versions of the same molecule.

This distinction has become increasingly important as researchers investigate whether the two pathways can be targeted together.

Why Has GLP-1 Received So Much Attention?

GLP-1 receptor signalling has been researched for decades.

One major area of interest involves its role in glucose-dependent insulin secretion.

The development of longer-acting GLP-1 receptor agonists allowed researchers to investigate sustained activation of the pathway.

This ultimately led to a large body of clinical research.

However, metabolism isn’t controlled by GLP-1 alone.

Numerous hormones and signalling systems interact to regulate energy balance and glucose metabolism.

That has encouraged researchers to investigate additional targets.

Why Is Amylin Research Growing?

Amylin isn’t a newly discovered hormone.

What has changed is the development of modified amylin analogues and multi-pathway compounds that make the pathway increasingly relevant to modern metabolic research.

Naturally occurring human amylin has characteristics that make pharmaceutical development challenging, including a tendency to aggregate.

Researchers have therefore developed modified analogues with different pharmacological properties.

One prominent example is cagrilintide.

What Is Cagrilintide?

Cagrilintide is a long-acting amylin analogue being investigated by Novo Nordisk.

It provides researchers with a way to study sustained amylin-related signalling.

But cagrilintide has attracted particular attention because researchers are also studying it alongside a GLP-1 receptor agonist.

That combination is known as CagriSema.

Why Combine Amylin and GLP-1?

This is where the distinction between the two hormones becomes especially interesting.

Because amylin and GLP-1 use different receptor systems, researchers can investigate whether targeting both provides biological effects that differ from targeting either pathway individually.

CagriSema combines:

Cagrilintide — amylin analogue

• ●

Semaglutide — GLP-1 receptor agonist

Rather than simply increasing activity at one receptor, this approach investigates two complementary hormonal pathways.

It reflects a much broader change occurring within metabolic research.

Where Does Zenagamtide Fit?

Zenagamtide, previously known as amycretin, represents another approach.

Rather than combining cagrilintide and semaglutide as two components, zenagamtide is being investigated as a single molecule with GLP-1 and amylin receptor agonist activity.

That creates an interesting scientific distinction:

CagriSema: combination of separate GLP-1 and amylin-related components.

Zenagamtide: GLP-1/amylin co-agonism incorporated into one investigational molecule.

Both demonstrate the increasing interest in studying these pathways together.

What About Retatrutide?

Retatrutide demonstrates another direction in multi-pathway research.

It doesn’t target the amylin pathway.

Instead, retatrutide is designed to activate three receptors:

GIP + GLP-1 + glucagon

It is therefore described as a triple receptor agonist.

Comparing these research strategies illustrates just how quickly the field has expanded.

Researchers aren’t simply developing different versions of GLP-1 receptor agonists.

They’re investigating entirely different combinations of metabolic signalling systems.

Amylin vs GLP-1 Receptors

There is also an important difference at receptor level.

GLP-1 acts through the GLP-1 receptor.

Amylin signalling is more complex.

Functional amylin receptors are formed through interactions involving the calcitonin receptor and receptor activity-modifying proteins, commonly called RAMPs.

That distinction is one reason describing amylin as simply another GLP-1-like hormone would be inaccurate.

Their downstream physiological effects may overlap in some areas, but the underlying receptor biology is different.

Are Amylin Analogues Peptides?

Yes.

Amylin itself is a peptide hormone, and compounds designed to mimic or modify amylin signalling can be peptide-based molecules.

But the word “peptide” describes a very broad molecular category.

It doesn’t tell us what a compound does.

Two peptides can have completely different biological functions depending on their amino-acid sequences, structures and receptor targets.

For scientific research, understanding the mechanism and receptor system is therefore much more informative than simply identifying something as a peptide.

Is Amylin Replacing GLP-1?

No.

Current research isn’t best understood as amylin replacing GLP-1.

Instead, scientists are investigating whether multiple metabolic pathways can complement one another.

This is part of a wider evolution in the field:

GLP-1 receptor agonism

→ dual receptor agonism

→ triple receptor agonism

→ GLP-1/amylin combinations and co-agonists

→ additional emerging metabolic pathways

The result is a considerably more diverse research landscape than existed only a few years ago.

Why the Amylin vs GLP-1 Question Matters

Understanding the distinction between amylin and GLP-1 makes many of today’s emerging research programmes easier to understand.

Cagrilintide investigates amylin signalling.

Semaglutide targets the GLP-1 receptor.

CagriSema combines the two approaches.

Zenagamtide investigates GLP-1 and amylin receptor activity within one molecule.

Retatrutide follows another route entirely through GIP, GLP-1 and glucagon receptors.

Rather than viewing these compounds simply as variations of one another, their different mechanisms reveal something more interesting: modern metabolic research is increasingly becoming multi-pathway research.

As new clinical evidence emerges, researchers should gain a clearer understanding of how these pathways interact and which combinations warrant further investigation.

Research Notice: This article is for educational and scientific-information purposes only. References to investigational compounds do not imply regulatory approval or established medical use. This article does not provide medical advice, dosing information or treatment guidance.